0.1154

0.86% -0.001

After Hours: .11 -0.0054 -4.68%

Cns Pharmaceuticals Inc (CNSP)

Overview News Price History Financials Discussions Forecast Stock Split

Cns Pharmaceuticals Inc stock is traded at $0.1154, with a volume of 1.94M. It is down -0.86% in the last 24 hours and down -12.71% over the past month. CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Previous Close:

$0.1164

Open:

$0.1179

24h Volume:

1.94M

Relative Volume:

0.14

Market Cap:

$6.77M

Revenue:

Net Income/Loss:

$-18.61M

P/E Ratio:

-0.0115

EPS:

-10.05

Net Cash Flow:

$-13.91M

1W Performance:

-6.63%

1M Performance:

-12.71%

6M Performance:

-98.90%

1Y Performance:

-99.90%

1-Day Range:

$0.1134

$0.118

1-Week Range:

$0.11

$0.145

52-Week Range:

$0.0955

$116.00

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Name

Cns Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

1-800-946-9185

Address

2100 WEST LOOP SOUTH, HOUSTON

Employee

Twitter

Next Earnings Date

2024-11-13

Latest SEC Filings

CNSP's Discussions on Twitter

Compare CNSP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CNSP Cns Pharmaceuticals Inc	0.1154	6.77M	0	-18.61M	-13.91M	-10.05
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Stock (CNSP) Latest News

Nov 25, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - AccessWire

Nov 25, 2024

CNS Pharma's Berubicin Shows Higher Patient Retention in Pivotal GBM Trial | CNSP Stock News - StockTitan

Nov 25, 2024

Nov 23, 2024

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - GuruFocus.com

Nov 23, 2024

CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 4.3% – Here’s What Happened - Defense World

Nov 23, 2024

CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 19, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart

Nov 19, 2024

Nov 18, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart

Nov 18, 2024

CNS Pharmaceuticals to Present Berubicin GBM Trial Data at SNO 2024 Annual Meeting | CNSP Stock News - StockTitan

Nov 18, 2024

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - AccessWire

Nov 18, 2024

Nov 15, 2024

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire

Nov 15, 2024

CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan

Nov 15, 2024